전체 프로그램

AntibodystaleZibo Municipal HospitalPhase 2

SBRT combined with Tislelizumab followed by Tislelizumab (SBRT combined with Tislelizumab followed by Tislelizumab)

NSCLC; Tislelizumab · FRα

CGTBiologicstaleSeattle Children's HospitalPhase 1

SC-CAR4BRAIN (SC-CAR4BRAIN)

Diffuse Intrinsic Pontine Glioma; Diffuse Midline Glioma · FRα

ADCBiologicstaleSorrento Therapeutics, Inc.Phase 1

STI-3258 (STI-3258)

Relapsed Solid Neoplasm; Refractory Cancer · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3

CGTBiologicstalePersonGen BioTherapeutics (Suzh…Phase 1

T cell injection targeting B7-H3 chimeric antigen receptor (T cell injection targeting B7-H3 chimeric antigen receptor)

B7-H3-positive Relapsed/ Refractory Neuroblastoma · FRα

CGTBiologicstalePersonGen BioTherapeutics (Suzh…Phase 1

T cell injection targeting FLT3 chimeric antigen receptor (T cell injection targeting FLT3 chimeric antigen receptor)

FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia · FRα

CGTBiologicstaleNational Cancer Institute (NCI)Phase 1

T-cell receptor alternate reading frame protein (TARP, T-cell receptor alternate reading frame protein, T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine)

Prostate Specific Antigens; Prostate Neoplasms · FRα

CGTBiologicstaleNational Cancer Institute (NCI)Phase 1

T-cell receptor alternate reading frame protein (TARP, T-cell receptor alternate reading frame protein, T-cell receptor alternate reading frame protein (TARP) peptide vaccine)

Prostate Specific Antigens; Prostate Neoplasms · FRα

AntibodystaleJanssenPhase 2

Teclistamab Monotherapy (Teclistamab Monotherapy)

Relapse Multiple Myeloma; Refractory Multiple Myeloma · FRα

AntibodystaleJanssenPhase 2

FDA-approved (Teclistamab, Teclistamab(FDA-approved))

Multiple Myeloma; Cytokine Release Syndrome · FRα

AntibodystaleHoffmann-La RochePhase 3

Tociluzumab (Tociluzumab)

Relapsed or Refractory Follicular Lymphoma · FRα

#FR#Antibody#Phase3#항체#면역항체+3

AntibodystaleRochePhase 2

Trifluridine-tipiracil plus Bevacizumab Alone (Trifluridine-tipiracil plus Bevacizumab Alone)

Refractory Metastatic Colorectal Cancer · FRα

#FR#Antibody#Phase2#항체#면역항체+3

CGTBiologicstaleCellectis S.A.Phase 1

UCART123v1.2 (UCART123v1.2)

Relapsed/Refractory Acute Myeloid Leukemia · FRα

CGTBiologicstaleCellectis S.A.Phase 1

UCARTCS1A (UCARTCS1A)

Relapsed/Refractory Multiple Myeloma · FRα

CGTAAVBiologicstaleYAP Therapeutics, Inc.Phase 1

AAV9-Sav-shRNA (YAP101, YAP101 (AAV9-Sav-shRNA))

Heart Failure With Reduced Ejection Fraction · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+3

AntibodystaleNational Cancer Institute (NCI)Phase 1

aflibercept (Eylea, VEGF Trap-Eye, Eylea HD, Ziv-Aflibercept)

Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Colorectal Carcinoma · FRα

#FR#Antibody#Phase1#항체#면역항체+4

AntibodystaleNational Cancer Institute (NCI)Phase 2

apolizumab (apolizumab)

Noncontiguous Stage II Small Lymphocytic Lymphoma; Recurrent Small Lymphocytic Lymphoma · FRα

CGTBiologicstaleBeijing GoBroad HospitalPhase 1

autologous FL-33 CAR T therapy (autologous FL-33 CAR T therapy)

Refractory/Relapsed Acute Myeloid Leukaemia · FRα

CGTBiologicstaleXiangyang No.1 People's HospitalPhase 2

autologous NK cell (autologous NK cell)

NK Cell; B-cell Lymphoma Recurrent · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4

효능 ORR 0.667%임상시험 1상태 RECRUITING

CGTBiologicstaleYuLiPhase 2

dual target CAR-T cell therapy (dual target CAR-T cell therapy)

Lymphoma, B-Cell; Relapse/Recurrence · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+5